We found that at 100 μg dosage, α‐PD‐L1 did not significantly inhibit LLC tumor growth (Figure 6B–D), consistent with previous reports.[25] Knockdown of Rfwd3 inhibited tumor growth and significantly improved the therapeutic efficacy of α‐PD‐L1 (Figure 6B–D). Here, RFWD3 is linked to neoplasm.